The WFI Beyond Standard
Why "meets WFI" is only a floor - and the beyond-compendial standard that raises it, defined and proven attribute by attribute.
Water for Injection is the one input shared by every buffer, every medium and the final formulation, so its quality sets the ceiling for everything built on it - and a deficiency in it stays hidden until late, when it is most expensive to fix. This briefing sets out why the pharmacopoeial monograph is a starting point rather than a finish line, and introduces the WFI Beyond Standard: a defined, published specification - now including all 24 ICH Q3D elemental impurities - proven lot by lot on the Certificate of Analysis. Processes that adopt it carry the mark Built on WFI Beyond.
Built on WFI Beyond the mark for the water beneath a molecule that earns it.
In-Depth · Industry Edition D02 · Rev 2.3 · 29 Sep 2026 · Author: Jens Hartmann, CEO, PAN-Biotech & PAN-Celltech · a briefing for pharma, biotech & CDMO teams.
Key takeaways
- The WFI Beyond Standard is a defined, published, beyond-compendial standard for the water beneath a biologic - not a marketing claim but a specification, written down and proven lot by lot on the Certificate of Analysis.
- Water for Injection is the most underestimated raw material in biologics: it feeds nearly every buffer, medium and final formulation, so a deficiency in the water cascades into the whole process - and surfaces late, as silent stability loss or a failed Phase 1-3 time-point, when it is most expensive to unwind.
- "Meets WFI" is a floor, not a ceiling: the monograph, whose core dates to 1969, sets a minimum - two waters can both be legitimate WFI yet differ greatly on the attributes advanced biologics depend on.
- The standard sets: endotoxin >50x below the limit, TOC 10x below, conductivity >5x below (typical results lower still), nuclease-free, sterile, animal-component-free - and, uniquely for water, a defined specification for all 24 ICH Q3D elemental impurities, each quantified by ICP-MS on every lot.
- Copper and iron are the two metals that catalyse antibody oxidation - and iron is the one that neither the water monograph nor ICH Q3D requires you to measure. WFI Beyond measures both; on the reference lot copper and iron were both < LOQ.
- One water backs every modality - antibodies, mRNA & LNP, cell & gene therapy, vaccines, recombinant proteins - what changes is which attribute matters most.
- Backed by a filed FDA Type IV (excipient) Drug Master File (MF044505); DPBS carries a companion Type IV DMF (MF044371) - referenceable through a Letter of Authorization.
- One matched standard spans research grade (P-series) to GMP (CT-series), so a programme qualifies once and scales without re-qualifying the water. A process that adopts it is Built on WFI Beyond. WFI Beyond is opt-in.
Qualify once, scale without re-qualifying
The same water runs on a matched continuum from the bench to commercial fill. Raise the quality ceiling with WFI Beyond wherever a sensitive molecule earns it.
Founded on water
In 1988, in the village of Aidenbach in Lower Bavaria, PAN-Biotech was founded for one simple reason: the water. The region sits on what the company's founders considered some of the finest well water in Europe - and the conviction was not eccentric. A few kilometres away, the Cistercian monks of Kloster Aldersbach had been brewing beer on the very same groundwater since 1268 - among the oldest documented breweries in the world. The parallel runs deeper than the water alone: brewing is itself a biological process - yeast cultured in water to harvest a product - the very principle on which modern cell culture, and the biologics industry PAN-Biotech serves, is built.
For the 38 years since, that water has been the quiet foundation of PAN-Biotech's cell-culture media - the products that made the company's name with biologics developers worldwide. Then PAN-Celltech was founded to carry that same foundation forward into GMP: to bring the group's decades of water and bioprocess expertise to the demands of regulated, clinical-grade manufacturing. PAN-Biotech is the master brand; PAN-Celltech is its dedicated GMP arm - a branded house, not a rename.
A heritage built on water, and a company built to bring it to GMP. WFI Beyond is where those two threads meet.
Section 2The most underestimated raw material
In any biologics process, Water for Injection is everywhere and noticed nowhere. It is the base of almost every buffer and medium, and it is the vehicle for the final formulation that goes into the vial. No other single input touches so many stages of the process - or so many different kinds of processes.
That ubiquity is exactly why it is dangerous to underestimate. Because the water flows into nearly every step, its quality cascades into all of them: a deficiency in the water is not contained to one buffer - it is distributed across the entire process. The most ordinary-looking component is, at GMP scale, one of the hardest to guarantee consistently and to document. You can source the purest amino acids on the planet, but if the water is compromised, the batch is compromised.
"Just water" - until you need it nuclease-free, at an endotoxin level far below the monograph, and assured batch after batch.
Section 3One water, every modality
What makes WFI unique among raw materials is that it is not specific to any one product. Antibodies, mRNA, cell and gene therapies, vaccines and recombinant proteins are built on profoundly different biology - but all of them rest on the same water. What changes from one modality to the next is not whether water quality matters, but which attribute matters most - and the same WFI Beyond specification answers all of them:
| Modality | What matters most in the water | Why |
|---|---|---|
| Monoclonal antibodies | Low trace metals; ultra-low endotoxin | Trace metal ions catalyse oxidation and drive aggregation, threatening stability; pyrogen control is essential in an injectable. |
| mRNA & LNP products | Nuclease-free (RNase) | Residual RNase degrades the mRNA payload - a direct hit to potency; for these products it is the single most important water attribute. |
| Cell & gene therapy | Ultra-low endotoxin; nuclease-free; sterility | Sensitive primary cells and nucleic-acid cargo, often patient-proximate, leave no margin for pyrogens or contamination. |
| Vaccines | Endotoxin control and sterility at scale | Pyrogen safety and batch-to-batch consistency must hold across large production volumes. |
| Recombinant proteins | Low endotoxin and organic carbon | Purity and pyrogen control protect the final product and keep the process clean. |
Read down the table and the conclusion is hard to miss: the case for a higher water standard does not weaken as you move beyond antibodies - it strengthens. For mRNA and cell & gene therapy in particular, the attributes that distinguish a premium WFI are not a refinement; they are central to whether the product works at all.
Section 4Beyond the monograph: what a premium water controls
"Water for Injection" is a pharmacopeial grade. To carry the name, water must meet a defined monograph - limits on conductivity, organic carbon, endotoxin and so on. That is a meaningful bar. But it is a floor, not a ceiling: it describes the minimum a water must clear to be called WFI, not the quality a particular batch delivers. Two waters can both be entirely legitimate WFI and still be worlds apart on the attributes that matter to an advanced biologic - because the monograph was written for injectable water in general, not for the specific vulnerabilities of these molecules. The European standard dates back to the first European Pharmacopoeia, published in 1969, its limits framed in, and for, the medicine of that era.
The "cracks" a modern biologic falls through are specific, and each maps to an attribute of the water: endotoxin (pyrogenic, a direct patient-safety concern); nucleases (residual RNase/DNase that degrade nucleic acids - a potency risk for mRNA and gene therapy); trace / elemental impurities (copper and iron - the two metals that catalyse antibody oxidation by Fenton chemistry and drive aggregation, invisible to conductivity, and one of them - iron - beyond what any water monograph or even ICH Q3D asks you to measure); organic carbon (a general purity marker); and animal origin (a TSE/BSE question that runs through every filing). And the questions no longer end where the 1969 monograph does - a biologic reaching a patient today must clear impurity classes the monograph never named: elemental impurities (ICH Q3D), residual solvents (Q3C), nitrosamines (current EMA guidance, the class that forced global recalls from 2018) and TSE/BSE safety (animal-component-free). WFI Beyond starts from that end.
Get the water wrong and you rarely find out on day one. You find out in month eighteen - in a failed stability time-point, a lost lot, a programme stalled deep in the clinic - which is exactly why the bar belongs at the start, not the floor.
Section 5The WFI Beyond Standard, defined
A standard is not a claim - it is something written down, measurable, and demandable. That is the difference between a premium water and a standard, and it is why this section matters: here the WFI Beyond Standard is set out attribute by attribute, each with a defined specification and a real measured result. "Beyond compendial" becomes a measured fact, proven lot by lot on the Certificate of Analysis. The proof reads in three columns - the pharmacopoeia floor, the WFI Beyond specification, and the actual result measured on a real production batch - so the gap is visible, not asserted:
| Attribute | Ph. Eur. 0169 limit | WFI Beyond spec | Result, real batch |
|---|---|---|---|
| Conductivity (20 °C) | ≤ 1.1 µS/cm | ≤ 0.2 µS/cm | 0.128 µS/cm |
| Total organic carbon | ≤ 0.5 mg/L | ≤ 0.05 mg/L | 0.011 mg/L |
| Endotoxin | ≤ 0.25 EU/mL | < 0.005 EU/mL | < 0.005 EU/mL |
| Elemental impurities | not in monograph | < ICH Q3D limit | 24 elements by ICP-MS; 22 < LOQ, Sb & Cr thousands-fold below limit |
| Nuclease activity | not in monograph | none detected | RNase & DNase not detected |
| Sterility | – | sterile · single-use | no growth |
| Animal origin | – | animal-component-free | TSE/BSE safety (signed declaration) |
| Regulatory | – | Type IV DMF | MF044505 (FDA excipient) |
These are not target or typical figures: each is the actual result measured on a real production batch (Art. CT-981000, Lot 2560826), as reported on its Certificate of Analysis. The WFI Beyond specification alone sits >5x below the pharmacopoeia on conductivity, 10x below on TOC and >50x below on endotoxin - and the measured batch result is lower still. LOQ = limit of quantification, the level below which a value cannot be reliably measured, i.e. effectively "not detectable".
Applying ICH Q3D to water is a first: the WFI monograph does not call for it, and it is a finished-drug standard. WFI Beyond runs it anyway - all 24 elemental impurities by ICP-MS against the ICH Q3D parenteral limits, the actual values reported on every Certificate of Analysis, not a pass/fail. And the questions the monograph never asks are answered up front: WFI Beyond carries a signed BSE/TSE & ICH Q3 declaration - manufactured from raw materials of non-animal origin and out of scope of the EMA TSE/BSE guidance (EMA/410/01 Rev. 3), with residual solvents (ICH Q3C), nitrosamines (EMA) and elemental impurities (ICH Q3D) risk-assessed across every product-contact material.
The 24 elements, in full - the part of the standard no water monograph defines
This is the heart of the standard, and the part that is genuinely new: the Ph. Eur./USP water monograph sets no limit on elemental impurities at all. The WFI Beyond Standard gives each of the 24 ICH Q3D elements a defined specification and reports its measured value on every lot. The specification is set conservatively - at 50% of the ICH Q3D parenteral limit for each element as a launch criterion - so it is reliably met and can only be tightened over time, never widened. All values in µg/L; elements in ICH Q3D class order.
| Element | Class | ICH Q3D limit (µg/L) | WFI Beyond spec (µg/L) | LOQ (µg/L) | Result, real batch (µg/L) |
|---|---|---|---|---|---|
| Arsenic (As) | 1 | 1 500 | ≤ 750 | 0.30 | < LOQ |
| Cadmium (Cd) | 1 | 200 | ≤ 100 | 0.04 | < LOQ |
| Mercury (Hg) | 1 | 300 | ≤ 150 | 0.06 | < LOQ |
| Lead (Pb) | 1 | 500 | ≤ 250 | 0.10 | < LOQ |
| Cobalt (Co) | 2A | 500 | ≤ 250 | 0.10 | < LOQ |
| Nickel (Ni) | 2A | 2 000 | ≤ 1 000 | 0.40 | < LOQ |
| Vanadium (V) | 2A | 1 000 | ≤ 500 | 0.20 | < LOQ |
| Silver (Ag) | 2B | 1 000 | ≤ 500 | 0.20 | < LOQ |
| Gold (Au) | 2B | 10 000 | ≤ 5 000 | 2.0 | < LOQ |
| Iridium (Ir) | 2B | 1 000 | ≤ 500 | 0.20 | < LOQ |
| Osmium (Os) | 2B | 1 000 | ≤ 500 | 0.20 | < LOQ |
| Palladium (Pd) | 2B | 1 000 | ≤ 500 | 0.20 | < LOQ |
| Platinum (Pt) | 2B | 1 000 | ≤ 500 | 0.20 | < LOQ |
| Rhodium (Rh) | 2B | 1 000 | ≤ 500 | 0.20 | < LOQ |
| Ruthenium (Ru) | 2B | 1 000 | ≤ 500 | 0.20 | < LOQ |
| Selenium (Se) | 2B | 8 000 | ≤ 4 000 | 1.60 | < LOQ |
| Thallium (Tl) | 2B | 800 | ≤ 400 | 0.16 | < LOQ |
| Barium (Ba) | 3 | 70 000 | ≤ 35 000 | 14.00 | < LOQ |
| Chromium (Cr) | 3 | 110 000 | ≤ 55 000 | 22.00 | ~0.3 |
| Copper (Cu) - key for antibody oxidation | 3 | 30 000 | ≤ 15 000 | 6.00 | < LOQ |
| Lithium (Li) | 3 | 25 000 | ≤ 12 500 | 5.00 | < LOQ |
| Molybdenum (Mo) | 3 | 150 000 | ≤ 75 000 | 30.00 | < LOQ |
| Antimony (Sb) | 3 | 9 000 | ≤ 4 500 | 1.80 | 0.7-2.6 |
| Tin (Sn) | 3 | 60 000 | ≤ 30 000 | 12.00 | < LOQ |
ICH Q3D limit = parenteral permitted daily exposure expressed as a concentration (Option 1, 10 g/day). The result column holds the actual values measured on a real production batch (Art. CT-981000, Lot 2560826), not typical or target figures. LOQ = limit of quantification of the accredited laboratory - the lowest concentration the validated ICP-MS method can reliably measure (shown per element, as on the Certificate of Analysis); results below it are reported as "< LOQ". On this lot 22 of the 24 were < LOQ; only antimony and chromium registered, each far below the WFI Beyond spec. Elemental specifications are the working WFI Beyond Standard, being finalised with QA against the laboratory's per-element LOQ; the exact figures are confirmed at publication.
The two metals that oxidise an antibody - copper and iron
Of the 24 elements, two matter to a monoclonal antibody out of all proportion to the rest, for one reason: they catalyse oxidation. Oxidative damage to an antibody is overwhelmingly metal-catalysed - Fenton chemistry, in which a redox-active metal ion cycles between oxidation states and, with the traces of peroxide and oxygen present in any process, generates radicals that attack methionine, histidine and tryptophan. What follows is the failure mode that ends programmes late: charge variants, loss of potency, fragmentation and, above all, aggregation - the developability problems that appear not on day one but deep in CMC, where they are hardest and most expensive to fix.
The two catalysts are copper and iron. Copper is the most potent per mole - it binds histidine-rich sites on the antibody and does targeted damage at parts-per-billion levels; iron is the most ubiquitous, leaching from stainless steel and water systems into everything downstream. And this is the gap the WFI Beyond Standard closes: the water monograph tests neither metal, and ICH Q3D - a toxicity framework - covers copper but not iron. A water can be fully compendial and fully ICH Q3D-clean and still carry the iron that oxidises an antibody. WFI Beyond measures both - on the reference lot, copper and iron were both below the limit of quantification - reported on the Certificate of Analysis and, for the oxidation pair specifically, in a dedicated oxidation-metals addendum.
Copper and iron are the two metals that oxidise an antibody. One of them - iron - no water monograph and not even ICH Q3D requires you to measure. WFI Beyond measures both, and proves them lot by lot.
A standard you can point to - and pass on
The most valuable component in a process is often the one no one can see. The WFI Beyond Standard makes the invisible nameable: a defined water specification a developer can design to, a CDMO can standardise on, a sponsor can carry into a filing, and a partner or investor can recognise in diligence. That is what turns an ingredient into a standard - the same idea that let an unseen component become a mark buyers came to expect.
Built on WFI Beyond is that mark: a short, honest signal that the water beneath a process meets the standard set out here - beyond compendial, all 24 ICH Q3D elements specified and measured, DMF-backed, proven lot by lot.
From source to single-use bag
A premium source is the beginning of the story, not the end of it. WFI quality is ultimately made by purification and control, not by the well alone - and then proven by testing and documentation. WFI Beyond is manufactured by PAN-Celltech under EU GMP Annex 1 (a capability and a standard, which is why we describe our manufacture as GMP-compliant and audit-proven rather than "certified"), with aseptic filling validated by routine media fills twice a year and an ICH-format stability study supporting a two-year shelf life at +15 to +25 °C.
Sterility rests on a validated aseptic process. The bulk water is sterile-filtered through a 0.1 µm filter - a full grade tighter than the 0.2 µm sterilising filter most processes rely on - and is then filled aseptically, under EU Annex 1, into single-use containers that have themselves been gamma-irradiated to a validated 10⁻⁶ Sterility Assurance Level before filling. The product-contact path is entirely single-use and replaced for each batch, so there is no shared, multi-product equipment and no batch-to-batch carry-over; the film is screened for extractables. The standard formats are single-use bottles and bags - from 500 mL and 1000 mL bottles to bags from 1 to 1000 litres - and, on request, custom formats from 1 mL tubes upwards. So the same qualified water follows you from development to production, across every modality and at whatever scale a step needs, without re-qualifying the supply.
Section 7The DMF advantage: a regulatory keystone
Of everything in that package, the Drug Master File does the most work. A DMF is a confidential dossier filed with the FDA that captures exactly how a product is made and controlled - sourcing, equipment, cleaning validations, quality-control limits, stability data. You reference it in your own submission through a Letter of Authorization, so the authority can rely on it in full without your team ever obtaining, holding or recreating it - and without proprietary detail being exposed in either direction.
WFI Beyond is backed by a filed FDA Type IV DMF (MF044505) - and the type matters: Type IV is the FDA's category for excipients, which is exactly what water is in a finished drug product. The group holds a filed DPBS Type IV DMF (MF044371) alongside it. For an input as fundamental as water, that is the difference between buying from a supplier and building on a regulatory partner: it removes one of the heaviest items a lean QA function would otherwise build from scratch, and measurably de-risks and shortens the filing.
Section 8The proof at commercial scale
WFI Beyond is filled by the same PAN-Celltech GMP liquid operation that has proven itself at commercial scale across the group's products:
And on the water specifically: every lot of WFI Beyond is released against its full beyond-compendial panel - endotoxin >50x below the WFI limit, TOC 10x below, all 24 elemental impurities quantified on the Certificate of Analysis. The ~50,000 L and ~150,000 L stories are anonymised customer case studies - read them in full in the Knowledge Hub. Track-record figures are anonymised; capacity figures are stated as "up to".
The failure everyone fears most - and why it starts in the water
Across the industry, one fear comes back more than any other - that a promising therapy fails in the clinical phases, after years of work and enormous sums are already committed. What makes it so feared is that it can hide. A finished biologic can clear every quality criterion on the day it is filled and still degrade silently in storage, over the months or years it sits in a vial or a frozen bag.
The culprits are the very trace impurities a release test tolerates - and water carries most of them into the process. Parts-per-billion of a metal ion can catalyse oxidation that unfolds a protein or breaks down a lipid nanoparticle; a residual nuclease keeps chewing at an mRNA payload; a small pH drift tips a formulation out of its stability window. None of it shows up on day one - it surfaces later as lost potency, aggregation or a failed stability time-point, sometimes deep into a Phase 1-3 study.
Because water is the one input shared by every buffer, medium and final formulation, controlling it up front is the highest-leverage de-risking a programme can do - which is why upgrading to WFI Beyond where a molecule earns it is among the cheapest insurance available against the most expensive kind of late failure.
- A personal note from the author, on why the group put extraordinary attention into the water beneath everything else.
What a premium water standard means for you
The story above is shared. The sections below translate it into the terms of a specific role - read yours, skip the rest.
One water you never have to change
The most useful thing a water standard can do for a research team is stop being a variable. Because the same water runs on a matched continuum - Sterile Water for Cell Culture in research grade (P-series) through WFI Quality Water and WFI Beyond in GMP grade (CT-series) - you can develop in research grade and scale to the identical qualified GMP water, and the chemistry beneath your process never changes on you.
For nucleic-acid work that matters twice over. WFI Beyond is nuclease-free (RNase & DNase not detected), so the water you prepare an mRNA buffer or an IVT reaction in is not quietly degrading the payload. And because the water is already characterised past the monograph - trace metals, endotoxin, organic carbon - the foundation under every buffer and formulation you build is a known quantity, not an assumption.
Ready to use on the floor - no still, no CIP, no waiting
The people running the suite feel water quality as daily friction, and buying WFI Beyond ready-to-use takes most of it away. There is no still or distribution loop to operate, sample, hold and troubleshoot, and no CIP/SIP of water systems: the water arrives sterile, single-use and released with a Certificate of Analysis, ready to draw straight into buffer preparation or final formulation. Because every product-contact part is single-use, there is no cleaning to validate and no batch-to-batch carry-over to manage on the floor.
It also keeps the line moving and scales with the process. On-stock supply means the water is on the shelf rather than a multi-week wait; consistent lot-to-lot chemistry means fewer deviations and mid-run surprises; and the format follows the process - 500 mL and 1000 mL bottles, single-use bags from 1 to 1000 L, down to custom 1 mL tubes - so the same qualified water moves from a small prep to full scale without re-qualifying the supply.
Buy the certificate, not just the litre
Water looks like the cheapest line on the quote, which is exactly why it is mispriced. The right lens is total cost of ownership: producing WFI in-house at GMP means owning the purification, the validation, the routine testing and - above all - the documentation burden, batch after batch. Sourcing it from a qualified partner tips that whole burden back over the fence: the water arrives sterile, single-use and released with a Certificate of Analysis, ready to use.
Held stock and single-use packaging are also insurance against the future you cannot forecast - a demand spike, an incumbent supply disrupted - absorbed without a fresh qualification each time. The reliability is proven at scale: an entire specialty portfolio bridged at ~150,000 L over ~2 years with zero rejections.
The documentation is the product
For a raw material that feeds an entire process, the assurance is as important as the litre. WFI Beyond is manufactured to GMP in an EU Annex 1 facility, with a Certificate of Analysis on every lot characterising the full beyond-compendial panel - endotoxin, TOC, conductivity, nuclease activity, all 24 elemental impurities, sterility and animal-origin status. Aseptic filling is validated by media fills twice a year, and a two-year shelf life is supported by an ICH-format stability study. Because water is an excipient in the finished drug, that same documentation is already filed with the FDA as a Type IV (excipient) Drug Master File your regulatory team can reference.
The single-use, product-contact path removes an entire class of QA questions: no shared, multi-product equipment and no batch-to-batch carry-over, with the container film screened for extractables. The site is yours to assess - on-site or remotely, in full or in part.
Reference our filing instead of re-proving the water
The centrepiece is the Drug Master File, and its type is the point. WFI Beyond is backed by a filed FDA Type IV DMF (MF044505) - Type IV being the FDA's excipient category, the correct classification for water in a finished drug - with a DPBS Type IV DMF (MF044371) alongside it. You cross-reference it in your IND/BLA through a Letter of Authorization, so you neither re-prove nor reverse-engineer the water, and PAN's proprietary detail stays in the FDA's confidential file.
The wider dossier is built to survive review. Beyond the compendial minimum, WFI Beyond documents the impurity classes a modern filing actually has to clear - elemental impurities (ICH Q3D, all 24 elements quantified), residual solvents (Q3C), nitrosamines (EMA guidance) and TSE/BSE safety (animal-component-free) - so the questions are answered before they are asked.
The cheapest insurance on the most expensive risk
The strategic case for a premium water is asymmetric. The spend is small - water is a fraction of the bill of materials - but the risk it controls is the largest a programme carries: a Phase 1-3 failure on something avoidable, a silent stability loss, a supply gap at the worst moment. De-risking the one input that touches every step is among the highest-leverage, lowest-cost moves available - and exactly the kind of CMC and supply-chain diligence investors and partners want to see.
It is also optionality. Because one water standard serves all four modalities, a pipeline can pivot (mAb → vaccine → mRNA → cell & gene) without re-qualifying its water, and scale from bench to commercial fill on the same qualified supply - backed by external recognition (Pharma Tech Outlook's "Top 10 CMOs in Europe", 2024) and a proven continuity record.
A qualified water you can build on - and offer to your clients
For a contract manufacturer, one DMF-backed, EU Annex 1, single-use water standard lets you standardise the most fundamental input across every client programme rather than qualifying a different water for each - one specification, one documentation and packaging standard, one audit story to maintain. Because water is an excipient in the finished drug, that water is filed with the FDA as a Type IV (excipient) Drug Master File your clients can reference directly in their own submissions - a regulatory asset you pass straight through to the sponsor.
Carry "Built on WFI Beyond" as your own mark. Adopting the standard is not only an internal simplification - it is something you offer outward. A sponsor whose programme runs on your line inherits a named, DMF-backed water standard it can reference in its own filing; you hand it a quality story and a regulatory asset, not just a manufacturing slot, and a badge that reassures its board, its auditors and its investors. It is a differentiator in every pitch, and one no commodity-water competitor can match.
Designed in early, it stays in - long-term. Because the standard is built into the process at development and cross-referenced through the DMF in the IND/BLA, it becomes part of the sponsor's validated process and regulatory dossier - so it travels with the product for its commercial life. Changing the water later would trigger re-qualification and a filing change, so programmes won on this standard tend to stay won: durable, recurring demand rather than one-off orders, with a switching cost that works in your favour. Standardising every client on one qualified water compounds that into a book of business that is stickier, simpler to run and easier to defend.
As a capacity partner, PAN-Celltech runs custom-formulated GMP (EU Annex 1) production, including private-label lines and single-use fill from 500 mL to 1000 L, with scale to match - combined output up to ~1.8 million litres a year - and a continuity record to underwrite it: an entire specialty portfolio bridged at ~150,000 L / ~300,000 bottles over ~2 years with zero rejections, and recognition among Pharma Tech Outlook's "Top 10 CMOs in Europe" (2024).
In one arc
A group founded on water in 1988 → nearly four decades of cell-culture chemistry → an EU Annex 1 GMP capability that fills water single-use and sterile → a defined standard engineered past the monograph on the attributes modern biologics actually depend on, all 24 ICH Q3D elements included → backed by a filed FDA Drug Master File. That standard has a name - the WFI Beyond Standard - and a mark, Built on WFI Beyond. For a modern biologic, water is the difference between complying and protecting; for a molecule that matters, nothing less makes sense.
Everything a qualification needs
The specification, a representative Certificate of Analysis, the BSE/TSE & ICH Q3 declaration, and a DMF Letter of Authorization on request.
DMF backing applies to WFI Beyond (MF044505) and DPBS (MF044371). Manufactured to GMP in an EU Annex 1 facility (a capability, not a certification); ISO 9001-certified QC laboratory.
The water portfolio
Research-grade sterile water for the bench, GMP WFI-quality water, and the beyond-compendial WFI Beyond standard. WFI Beyond is opt-in, ordered where a molecule earns it; larger formats and additional pack sizes are available on request.
| Product | Grade | Article no. | Pack / fill size | Regulatory |
|---|---|---|---|---|
| Sterile Water for Cell Culture | Research (RUO) | P04-991500 · P04-991000 · P04-99200B | 500 ml & 1000 ml bottles; 20 L bag; other sizes on request | Research use |
| WFI Quality Water | GMP · WFI (EP/USP) | CT-991500 · CT-991000 · CT-99010B · CT-99020B · CT-99050B · CT-99200B · CT-99500B | 500 ml & 1000 ml bottles; single-use bags 10 / 20 / 50 / 200 / 500 L; fill range 10 ml-1000 L on request | CoA per lot |
| WFI Beyond | GMP · beyond-compendial | CT-981500 · CT-981000 · CT-98001B · CT-98005B · CT-98010B · CT-98020B · CT-98050B · CT-98200B · CT-98500B · CT-981000B | 500 ml & 1000 ml bottles; single-use gamma-irradiated bags 1 / 5 / 10 / 20 / 50 / 200 / 500 / 1000 L; custom fills from 1 mL tubes on request | Filed FDA Type IV DMF (MF044505); CoA per lot |
One water standard, three grades. The research grade (P-series) and GMP grades (CT-series) share a matched continuum, so a programme can qualify once and scale without re-qualifying the water.
A real Certificate of Analysis - WFI Beyond
A representative production lot, as issued - the document speaks for itself. Art. CT-981000 (1000 mL) · Lot 2560826 · produced 18 Aug 2026 · sampled at beginning (B) and end (E) of fill.
| Specification | Ph. Eur. 0169 limit | WFI Beyond spec | Result (B / E) |
|---|---|---|---|
| Appearance - clarity / coloration | clear / colourless | clear / colourless | pass / pass |
| Conductivity (20 °C · 2.2.38) | ≤ 1.1 µS/cm | ≤ 0.2 µS/cm | 0.128 µS/cm |
| Total organic carbon (2.2.44) | ≤ 0.5 mg/L | ≤ 0.05 mg/L | 0.011 mg/L |
| Endotoxin (2.6.14 · Method C) | ≤ 0.25 EU/mL | < 0.005 EU/mL | < 0.005 / < 0.005 |
| RNase / DNase activity (AA 4.1.10) | not in monograph | none detected | not detected |
| Sterility (2.6.1) | – | no growth | no growth |
| Elemental impurities (2.4.20 · ICP-MS · 24 el.) | ICH Q3D parenteral | < Q3D limit | complies · 22/24 < LOQ |
Elemental impurities (ICH Q3D(R2), 24 elements by ICP-MS). 22 of 24 below the limit of quantification at both beginning and end of fill; the only two detected sit far below their parenteral limits - antimony 2.6 / 0.74 µg/L (limit 9.0 mg/L) and chromium 0.23 / 0.29 µg/L (limit 110 mg/L). Copper and iron - the two metals that catalyse antibody oxidation - were both below LOQ, reported in full in a dedicated oxidation-metals addendum. Backed by filed FDA Type IV (excipient) DMF MF044505; Made in Germany; 2-year shelf life at +15-25 °C. WFI Beyond is a raw material / excipient for compounding media, buffers and as a diluent for further manufacturing - not Sterile Water for Injection for direct human use.
Water, answered
What is the WFI Beyond Standard?
The WFI Beyond Standard is a defined, published, beyond-compendial standard for Water for Injection used as an excipient / for further manufacturing. It is a written specification - not a marketing claim - covering endotoxin (more than 50x below the compendial limit), total organic carbon (10x below), conductivity (more than 5x below), nuclease activity (RNase and DNase not detected), sterility, animal origin (animal-component-free), and - uniquely for water - all 24 ICH Q3D elemental impurities, each with a defined limit and quantified by ICP-MS on every lot. It is backed by a filed FDA Type IV (excipient) Drug Master File (MF044505) and proven lot by lot on the Certificate of Analysis.
What does "Built on WFI Beyond" mean?
"Built on WFI Beyond" is the travelling mark for a process whose water meets the WFI Beyond Standard. Because water is the invisible input beneath every buffer, medium and formulation, the mark makes that quality nameable: a developer can design to it, a CDMO can standardise on it, and a sponsor can carry it into a filing or diligence. It signals beyond-compendial water with all 24 ICH Q3D elements specified and measured, DMF support, and lot-by-lot proof.
What is WFI Beyond?
WFI Beyond is the product that meets the WFI Beyond Standard: Water for Injection engineered beyond the Ph. Eur./USP monograph and proven lot by lot on the Certificate of Analysis: endotoxin more than 50x below the compendial limit, total organic carbon 10x below, conductivity more than 5x below (typical results lower still), nuclease-free (RNase and DNase not detected), all 24 ICH Q3D elemental impurities quantified by ICP-MS, sterile, animal-component-free, and backed by a filed FDA Type IV (excipient) Drug Master File (MF044505).
Why is "meets WFI" a floor, not a ceiling?
The pharmacopoeial WFI monograph sets the minimum a water must clear to carry the name - it describes "good enough", not the quality a given batch delivers. Its core European definition dates to 1969 and was written for injectable water in general, not for the specific vulnerabilities of modern biologics. Two waters can both be legitimate WFI yet differ greatly on endotoxin, nucleases and trace metals - the attributes that matter to antibodies, mRNA and cell & gene products.
Which modalities need a premium water standard?
All of them - what changes is which attribute matters most. Monoclonal antibodies need low trace metals and ultra-low endotoxin (oxidation, aggregation, pyrogen control); mRNA and LNP products need nuclease-free water (RNase degrades the payload); cell & gene therapy needs ultra-low endotoxin, nuclease-free and sterility; vaccines need endotoxin control and sterility at scale; recombinant proteins need low endotoxin and organic carbon. The same WFI Beyond specification answers all of them.
Can I reference the Drug Master File in my submission?
Yes. WFI Beyond is backed by a filed FDA Type IV (excipient) DMF (MF044505); DPBS carries a companion Type IV DMF (MF044371). You cross-reference them in your IND/BLA through a Letter of Authorization, so the material is referenceable as exactly what it is in the drug product - an excipient - without your team rebuilding a dossier or PAN's proprietary detail being exposed.
Is the water animal-free, and is TSE/BSE covered?
Yes. The water is manufactured animal-component-free. A signed BSE/TSE & ICH Q3 declaration confirms non-animal origin (out of scope of EMA/410/01 Rev. 3) and documents a risk assessment for residual solvents (ICH Q3C), nitrosamines (EMA guidance) and elemental impurities (ICH Q3D) across every product-contact material.
Can I develop in research grade and move to GMP later?
Yes - that is the point of the continuum. The research grade (P-series) and the GMP grades (CT-series) are matched, so you qualify once and scale to the identical GMP water with no reformulation, from bench to commercial fill. WFI Beyond is opt-in, ordered exactly where a molecule earns it.
Is WFI Beyond for direct human use?
No. WFI Beyond meets the Ph. Eur./USP Water-for-Injection requirements and is controlled beyond them, but it is supplied for further manufacturing / as an excipient - for compounding media, buffers and as a diluent - and is not Sterile Water for Injection for direct reconstitution or direct human use.
Which formats and article numbers are available?
Bottles (500 & 1000 ml) and single-use, gamma-irradiated bags from 1 to 1000 L, plus custom fills from 1 mL tubes on request. WFI Beyond spans CT-981500 to CT-981000B; WFI Quality Water CT-991500 to CT-99500B; Sterile Water for Cell Culture P04-991500 to P04-99200B. The full list is in the portfolio appendix above.
Technical FAQ
74 technical questions on Water for Injection for biologics – trace metals and antibody oxidation, nuclease-free water for mRNA, LNP and cell & gene therapy, Drug Master Files, scale-up and specifications beyond the monograph – answered from this briefing.
Show all 74 technical questions
Trace metals and antibody oxidation (19)
Which trace metals cause monoclonal antibody oxidation?
Copper and iron are the two trace metals that catalyse monoclonal antibody (mAb) oxidation. Both are redox-active and, through Fenton chemistry, generate radicals that attack methionine, histidine and tryptophan – leading to charge variants, potency loss, fragmentation and aggregation. Conductivity cannot detect either metal at parts-per-billion (ppb) levels. PAN-Biotech's WFI Beyond is tested for copper by ICP-MS on every lot, iron is measured additionally, and both are reported in an oxidation-metals addendum.
What is Fenton chemistry, and why does it matter for biologics?
Fenton chemistry is a metal-catalysed oxidation reaction: a redox-active metal ion, such as copper or iron, cycles between oxidation states and – with the traces of peroxide and oxygen present in any process – generates radicals. In biologics, these radicals attack methionine, histidine and tryptophan, causing charge variants, potency loss, fragmentation and aggregation. Because water feeds almost every buffer and formulation, its copper and iron content is one controllable source of this risk.
How does copper in process water damage a monoclonal antibody?
Copper damages a monoclonal antibody by catalysing its oxidation. It binds histidine-rich sites and, via Fenton chemistry, generates radicals that attack methionine, histidine and tryptophan. Per mole, copper is the most potent of the two oxidation catalysts and acts at parts-per-billion levels – far below what conductivity can detect. The ICH Q3D parenteral limit for copper is 30,000 µg/L; on a reference lot of PAN-Biotech's WFI Beyond (lot 2560826), copper was below the LOQ of 6.00 µg/L.
Why is iron a risk to antibody stability even though ICH Q3D does not cover it?
Iron is a risk because it catalyses antibody oxidation through Fenton chemistry, yet ICH Q3D – a toxicity-based framework – does not include it, and the Ph. Eur. WFI monograph does not test for it. A water can therefore be fully compendial and ICH Q3D-compliant and still carry oxidising iron. PAN-Biotech measures iron in its WFI Beyond: on the reference lot it was below LOQ, reported in an oxidation-metals addendum.
Which amino acids are most vulnerable to metal-catalysed oxidation?
Methionine, histidine and tryptophan are the amino acid residues attacked when copper or iron ions generate radicals through Fenton chemistry. Oxidation at these sites can alter an antibody's charge profile and potency and can drive fragmentation and aggregation. Because the catalysing metals can enter with process water, controlling copper and iron in the water reduces one source of this risk. PAN-Biotech's WFI Beyond reports both metals in a dedicated oxidation-metals addendum.
What quality problems does metal-catalysed oxidation cause in antibodies?
Metal-catalysed oxidation causes four main quality problems in monoclonal antibodies: charge variants, loss of potency, fragmentation and aggregation. The damage starts when copper or iron ions generate radicals (Fenton chemistry) that attack methionine, histidine and tryptophan. These developability problems typically surface deep in CMC (chemistry, manufacturing and controls) rather than at release. Controlling trace metals in process water – for example with PAN-Biotech's WFI Beyond, which measures copper and iron – addresses one input-level source.
Why do oxidation-driven aggregation problems often appear late in development?
They appear late because oxidative damage accumulates in storage: a biologic can pass every release test on the day it is filled and still degrade over the following months. The damage then surfaces as lost potency, aggregation or a failed stability time-point, when it is most expensive to fix. Trace metals introduced with process water are one cause. Specifying water with measured copper and iron values, such as PAN-Biotech's WFI Beyond, moves this control to the start.
Where does iron contamination in a biologics process come from?
Iron commonly enters a biologics process by leaching from stainless steel and water systems, from where it is carried into buffers, media and formulations downstream. It is the most ubiquitous of the two metals that catalyse antibody oxidation, yet neither the Ph. Eur. WFI monograph nor ICH Q3D requires it to be measured. PAN-Biotech measures iron in its WFI Beyond and reports it in an oxidation-metals addendum (below LOQ on the reference lot).
Can conductivity testing detect trace metals in Water for Injection?
No. Conductivity cannot detect trace metals such as copper or iron at the parts-per-billion (ppb) levels that can catalyse antibody oxidation. A water can pass the Ph. Eur. 0169 conductivity limit (≤ 1.1 µS/cm at 20 °C) and still contain oxidising metals. Element-specific testing is needed: PAN-Biotech's WFI Beyond is tested for all 24 ICH Q3D elements by ICP-MS on every lot, and iron, which ICH Q3D does not cover, is measured additionally.
Why is ICP-MS used to test Water for Injection for elemental impurities?
ICP-MS is used because it measures each elemental impurity individually, which bulk tests cannot: conductivity does not detect metals at parts-per-billion levels. For PAN-Biotech's WFI Beyond, ICP-MS (Ph. Eur. 2.4.20) quantifies all 24 ICH Q3D elements on every lot, and the Certificate of Analysis reports the actual value and the limit of quantification (LOQ) for each element – not only pass/fail.
What is ICH Q3D, and does it apply to Water for Injection?
ICH Q3D is the ICH guideline on elemental impurities; ICH Q3D(R2) sets permitted daily exposures for 24 elements, which can be expressed as parenteral concentration limits (Option 1, 10 g/day). It is a finished-drug standard, and the Ph. Eur. WFI monograph does not require it for water. PAN-Biotech applies it to its WFI Beyond regardless: all 24 elements are quantified by ICP-MS on every lot and compared against the ICH Q3D parenteral limits.
What does "< LOQ" mean on a Certificate of Analysis?
"< LOQ" means the measured value is below the limit of quantification (LOQ) – the lowest concentration the validated method can reliably measure. In practice it means "effectively not detectable" at that method's sensitivity. On Certificates of Analysis for PAN-Biotech's WFI Beyond, the LOQ is shown per element; for copper it is 6.00 µg/L. On reference lot 2560826, 22 of the 24 ICH Q3D elements were reported as < LOQ.
How can I reduce the risk of metal-catalysed oxidation coming from my process water?
Specify process water whose copper and iron content is measured, not inferred from conductivity. Practical steps: ask for element-specific ICP-MS values per lot, not pass/fail; check that iron is measured, because ICH Q3D does not cover it; compare results with the ICH Q3D parenteral limits. PAN-Biotech's WFI Beyond provides ICP-MS data for all 24 ICH Q3D elements per lot plus an oxidation-metals addendum for copper and iron. Water control complements formulation development; it does not replace it.
Is there a Water for Injection that is tested for all 24 ICH Q3D elemental impurities on every lot?
Yes. PAN-Biotech's WFI Beyond, a beyond-compendial GMP Water for Injection, is tested by ICP-MS (Ph. Eur. 2.4.20) on every lot for all 24 ICH Q3D(R2) elements: Class 1 (As, Cd, Hg, Pb), Class 2A (Co, Ni, V), Class 2B (Ag, Au, Ir, Os, Pd, Pt, Rh, Ru, Se, Tl) and Class 3 (Ba, Cr, Cu, Li, Mo, Sb, Sn). Measured values appear on the Certificate of Analysis; iron is measured additionally.
How low can copper be in Water for Injection, and how is it measured?
Copper in Water for Injection is measured element-specifically by ICP-MS and can be below the limit of quantification. On a reference lot of PAN-Biotech's WFI Beyond (lot 2560826, produced 18 Aug 2026), copper was < LOQ (LOQ 6.00 µg/L). For context, the ICH Q3D parenteral limit is 30,000 µg/L. Conductivity cannot detect copper at these levels.
How can I find out the iron content of my Water for Injection?
Ask your supplier for a measured iron value from an element-specific method such as ICP-MS, because neither the Ph. Eur. WFI monograph nor ICH Q3D requires iron to be tested. Without it, iron – one of the two metals that catalyse antibody oxidation – remains unknown. PAN-Biotech's WFI Beyond reports iron in an oxidation-metals addendum: below LOQ on reference lot 2560826.
What does an ICP-MS elemental impurity result for Water for Injection look like in practice?
A useful ICP-MS result lists a measured value or "< LOQ" for each of the 24 ICH Q3D elements. On reference lot 2560826 of PAN-Biotech's WFI Beyond, 22 of the 24 were below LOQ at both beginning and end of fill. Only two were detected (beginning / end): antimony: 2.6 / 0.74 µg/L (ICH Q3D limit 9,000 µg/L); chromium: 0.23 / 0.29 µg/L (ICH Q3D limit 110,000 µg/L). Copper and iron were both < LOQ.
How should copper and iron be reported on a Water for Injection Certificate of Analysis?
Copper and iron are best reported as measured values with the method's LOQ, not as a pass/fail statement, because they are the two metals that catalyse antibody oxidation. Iron must be requested explicitly, since ICH Q3D does not cover it. PAN-Biotech's WFI Beyond reports both in a dedicated oxidation-metals addendum; on reference lot 2560826, copper and iron were both < LOQ.
Which Water for Injection should I use to prepare monoclonal antibody buffers and formulations?
Use Water for Injection whose trace metals and endotoxin are controlled beyond the monograph and documented per lot. PAN-Biotech recommends its WFI Beyond, an excipient for media, buffers and diluent, with ICP-MS data for all 24 ICH Q3D elements per lot, measured iron and endotoxin < 0.005 EU/mL. Confirm suitability in your own qualification; it is not for direct human use.
Nuclease-free water for mRNA, LNP and cell & gene therapy (16)
Why must water be nuclease-free for mRNA manufacturing?
Water must be nuclease-free because residual RNase degrades the mRNA payload, directly reducing potency. PAN-Biotech regards nuclease-free status as the single most important water attribute for mRNA and LNP products – and the Ph. Eur. WFI monograph does not test for it, so a compendial water can still carry nuclease activity. PAN-Biotech's WFI Beyond is specified as RNase and DNase "none detected"; on reference lot 2560826, neither was detected.
What is RNase, and how does it affect mRNA and LNP products?
RNase is a nuclease that degrades RNA. In mRNA and lipid nanoparticle (LNP) products, residual RNase in process water can degrade the mRNA payload, which directly hits potency – and the damage may not be visible on the day of release. Because the Ph. Eur. WFI monograph includes no nuclease test, nuclease-free status must be specified separately. PAN-Biotech's WFI Beyond specifies RNase and DNase activity as "none detected" and reports the result per lot.
Does the Ph. Eur. Water for Injection monograph test for nuclease activity?
No. The Ph. Eur. 0169 monograph for Water for Injection sets no requirement for RNase or DNase activity – nuclease activity is "not in monograph". A compendial WFI can therefore meet every monograph limit without any nuclease data. For mRNA, LNP and cell & gene therapy work, nuclease-free status has to be specified and tested separately. PAN-Biotech's WFI Beyond does this on every lot (method AA 4.1.10), with RNase and DNase not detected on the reference lot.
How can I verify that the water in my mRNA process is nuclease-free?
Verify nuclease-free status with lot-specific data, not a general claim. Check that the supplier's specification includes RNase and DNase activity, that each Certificate of Analysis reports a result for your lot, and that the test method is named. Compendial WFI release alone does not cover nucleases. For PAN-Biotech's WFI Beyond, the specification is "none detected" for RNase and DNase, tested per method AA 4.1.10 and reported per lot.
Where can I buy GMP Water for Injection that is RNase-free and DNase-free?
PAN-Biotech offers WFI Beyond, a GMP Water for Injection specified as nuclease-free: RNase and DNase activity "none detected". On reference lot 2560826 (produced 18 Aug 2026), both were not detected (method AA 4.1.10). It is manufactured by PAN-Celltech, the group's GMP arm, and is specified at endotoxin < 0.005 EU/mL. Request the specification and a representative CoA at info@pan-celltech.com.
How is nuclease activity tested in Water for Injection?
Nuclease activity is tested with a method defined in the supplier's specification, because the Ph. Eur. WFI monograph contains no RNase or DNase test. When qualifying water, ask for the method name, its sensitivity and a lot-specific result. PAN-Biotech tests its WFI Beyond for RNase and DNase per method AA 4.1.10 against "none detected".
What water should I use to prepare mRNA buffers and IVT reactions?
Use water that is documented nuclease-free per lot and low in endotoxin, because residual RNase degrades the mRNA payload. PAN-Biotech describes its WFI Beyond for exactly this use – preparing mRNA buffers and IVT reactions – with RNase and DNase not detected and endotoxin < 0.005 EU/mL. It is supplied as an excipient for further manufacturing, not for direct human use; qualify it in your own process.
What is endotoxin, and why does it matter in injectable biologics?
Endotoxin is a pyrogenic contaminant and a direct patient-safety concern in any injectable product. Because water feeds nearly every buffer, medium and final formulation, endotoxin in the water can be carried through the whole process. The Ph. Eur. 0169 limit for Water for Injection is ≤ 0.25 EU/mL; PAN-Biotech's WFI Beyond is specified at < 0.005 EU/mL (Ph. Eur. 2.6.14, Method C).
What endotoxin level is achievable in GMP Water for Injection beyond the Ph. Eur. limit?
Endotoxin levels far below the Ph. Eur. 0169 limit of ≤ 0.25 EU/mL are achievable: PAN-Biotech's WFI Beyond is specified at < 0.005 EU/mL, more than 50 times lower. Its reference lot 2560826 measured < 0.005 EU/mL at both beginning and end of fill (Ph. Eur. 2.6.14, Method C). Low endotoxin is relevant to all five modalities, especially monoclonal antibodies, cell & gene therapy and vaccines. Each lot is released with its own CoA.
Is the Ph. Eur. endotoxin limit of 0.25 EU/mL low enough for advanced biologics?
The Ph. Eur. limit of ≤ 0.25 EU/mL is a minimum for Water for Injection in general, not a target set for advanced biologics. Because water enters nearly every buffer, medium and final formulation, its endotoxin contribution is spread across the process. Where ultra-low endotoxin matters – monoclonal antibodies, cell and gene therapy, vaccines – a tighter specification adds margin: PAN-Biotech's WFI Beyond is specified at < 0.005 EU/mL (Ph. Eur. 2.6.14, Method C), and its reference lot 2560826 measured < 0.005 EU/mL at both beginning and end of fill. Whether the compendial limit is sufficient remains a decision for your own risk assessment.
Why is water quality critical in cell and gene therapy manufacturing?
Water quality is critical in cell and gene therapy because sensitive primary cells and nucleic-acid cargo, often patient-proximate, leave no margin for pyrogens or contamination. The three water attributes that matter most are ultra-low endotoxin, nuclease-free status and sterility, and the Ph. Eur. WFI monograph does not cover nuclease activity. PAN-Biotech's WFI Beyond is specified at endotoxin < 0.005 EU/mL and RNase/DNase "none detected", and is supplied sterile in single-use containers.
Which Water for Injection is suitable for cell and gene therapy manufacturing?
Cell and gene therapy needs Water for Injection with ultra-low endotoxin, documented nuclease-free status and sterility. PAN-Biotech's WFI Beyond is specified for all three: endotoxin < 0.005 EU/mL, RNase and DNase "none detected", and aseptic filling into gamma-irradiated single-use containers. It is supplied as an excipient for media, buffers and diluent, not for direct human use. Confirm suitability through your own qualification and change control.
How is the sterility of ready-to-use Water for Injection assured?
Sterility of ready-to-use Water for Injection rests on the supplier's validated aseptic process, which you should verify in the documentation or an audit. For PAN-Biotech's WFI Beyond, the bulk water is sterile-filtered (0.1 µm) and filled aseptically under EU GMP Annex 1 into containers gamma-irradiated to a 10⁻⁶ SAL. Media fills twice a year validate the process, and each lot is sterility-tested (Ph. Eur. 2.6.1).
How does a single-use product-contact path prevent batch-to-batch carry-over?
A single-use product-contact path prevents carry-over because every part that touches the product is used for one batch only and then replaced, so nothing can pass from one batch or product to the next. For PAN-Biotech's WFI Beyond, the entire product-contact path is single-use and replaced for each batch, there is no shared multi-product equipment, and the container film is screened for extractables. This removes a whole class of shared-equipment QA questions.
Why do some Certificates of Analysis report results at the beginning and end of fill?
Results at the beginning (B) and end (E) of fill cover both ends of a lot's filling run rather than a single sample point. The CoA for PAN-Biotech's WFI Beyond reports both: on reference lot 2560826, endotoxin was < 0.005 EU/mL at B and E, 22 of 24 elemental impurities were below LOQ at both points, and antimony (2.6 / 0.74 µg/L) and chromium (0.23 / 0.29 µg/L) were the only elements detected.
Which water grade should I use for mRNA research versus GMP production?
Use research-grade sterile water for bench work and GMP Water for Injection for production. At PAN-Biotech, that means Sterile Water for Cell Culture (P-Series, for research use only) for research, and the CT-Series – WFI Quality Water (EP/USP) or WFI Beyond – for GMP. For nucleic-acid work, WFI Beyond adds nuclease-free status and endotoxin < 0.005 EU/mL. PAN-Biotech positions the grades as a matched continuum; your change control still applies.
Drug Master Files and regulatory documentation (14)
What is a Drug Master File (DMF)?
A Drug Master File (DMF) is a confidential dossier filed with the US FDA that describes how a product is made and controlled – sourcing, equipment, cleaning validations, quality-control limits and stability data. A sponsor references it in its own submission through a Letter of Authorization, so the FDA can rely on it without the sponsor obtaining or holding the data. PAN-Biotech's WFI Beyond, for example, is backed by filed Type IV DMF MF044505.
What is a Type IV DMF?
A Type IV DMF is the FDA's Drug Master File category for excipients – the correct classification for water used in a finished drug product. It lets an excipient manufacturer file manufacturing and control information confidentially so that sponsors can reference it. PAN-Biotech's WFI Beyond is backed by a filed Type IV DMF (MF044505), and its DPBS by a companion Type IV DMF (MF044371).
Why is water treated as an excipient in a Drug Master File?
Water is treated as an excipient because that is its role in a finished drug product: it is the base of buffers and media and the vehicle of the final formulation, not the active substance. The FDA's Type IV (excipient) category is therefore the appropriate DMF type for water. PAN-Biotech's Type IV DMF for WFI Beyond (MF044505) lets sponsors reference the water as exactly what it is in the drug product – an excipient.
What is a Letter of Authorization (LoA) for a DMF?
A Letter of Authorization (LoA) is the document through which a sponsor is authorised to reference a supplier's Drug Master File in its own regulatory submission. With it, the FDA can rely on the DMF in full without the sponsor obtaining, holding or recreating the underlying data – and without proprietary detail being exposed in either direction. PAN-Biotech provides an LoA for its WFI Beyond DMF (MF044505) on request.
Can I see the contents of a supplier's DMF?
Generally not – a DMF is a confidential dossier held by the FDA, and that confidentiality is its purpose. You reference it through a Letter of Authorization, and the authority can rely on it in full without your team obtaining or holding it. For PAN-Biotech's WFI Beyond, DMF MF044505 stays confidential, while the company provides the specification, a representative CoA and the BSE/TSE & ICH Q3 declaration directly and offers site audits.
How does a DMF-backed water reduce the regulatory workload for a filing?
A DMF-backed water reduces workload because your submission cross-references the supplier's filed dossier instead of re-proving how the water is made and controlled. With a Letter of Authorization, the FDA can rely on the DMF, so your team does not rebuild that documentation. For PAN-Biotech's WFI Beyond, this is Type IV DMF MF044505, complemented by a signed BSE/TSE & ICH Q3 declaration. Your filing strategy remains your RA team's decision.
How do I reference an excipient supplier's DMF in an IND or BLA?
Reference an excipient supplier's DMF by including the supplier's Letter of Authorization (LoA) in your IND or BLA and cross-referencing the DMF number. Steps: 1) request the LoA from the DMF holder; 2) cross-reference the DMF for the excipient in your submission; 3) keep the specification, CoA and supporting declarations in your supplier file. Example: PAN-Biotech's WFI Beyond, Type IV DMF MF044505. Submission format follows your RA team's procedures.
Is there a DPBS buffer with a Type IV DMF that I can reference?
Yes. PAN-Biotech's DPBS is backed by a filed FDA Type IV (excipient) DMF, MF044371, which sits alongside the Type IV DMF for its WFI Beyond water (MF044505). Each can be referenced in a submission through a Letter of Authorization, so a sponsor can cover two process inputs through one supplier's filings.
How can a water supplier document nitrosamine and residual-solvent risk?
A water supplier can document these risks through a risk assessment across all product-contact materials, stated in a signed declaration. Neither nitrosamines nor residual solvents (ICH Q3C) are part of the Ph. Eur. WFI monograph. PAN-Biotech's signed BSE/TSE & ICH Q3 declaration for WFI Beyond covers nitrosamines (per current EMA guidance), residual solvents (ICH Q3C) and elemental impurities (ICH Q3D); request it with the specification and a representative CoA.
Which impurity classes does a modern biologics filing address beyond the WFI monograph?
A modern biologics filing addresses impurity classes the Ph. Eur. WFI monograph does not name: elemental impurities (ICH Q3D), residual solvents (ICH Q3C), nitrosamines (current EMA guidance) and TSE/BSE safety. For water, the supplier should document each one. PAN-Biotech's WFI Beyond does so through lot-by-lot ICP-MS for all 24 ICH Q3D elements and a signed BSE/TSE & ICH Q3 declaration with a Q3C and nitrosamine risk assessment across product-contact materials.
Which documents should I request when qualifying a Water for Injection supplier?
Request documents that prove quality lot by lot and support your filing: the specification; a representative Certificate of Analysis with actual values; a BSE/TSE and ICH Q3 declaration; a DMF Letter of Authorization, if you file with the FDA; audit access. PAN-Biotech provides all of these for WFI Beyond, including an LoA for Type IV DMF MF044505 and on-site or remote audits.
What should I check when auditing a Water for Injection manufacturer?
For ready-to-use sterile WFI, relevant audit topics include aseptic filling and media fills, sterile filtration, container sterilisation, the product-contact path, the QC laboratory and lot release. PAN-Celltech, manufacturer of PAN-Biotech's WFI Beyond, offers audits on-site or remotely, in full or in part, covering filling under EU GMP Annex 1 with media fills twice a year, 0.1 µm filtration, 10⁻⁶ SAL containers and an ISO 9001-certified QC lab.
What is ICH Q3C, and why does it matter for water used in biologics?
ICH Q3C is the ICH guideline on residual solvents. It matters for water because a modern biologics filing addresses residual solvents even though the Ph. Eur. WFI monograph does not name them. PAN-Biotech's WFI Beyond carries a signed BSE/TSE & ICH Q3 declaration that documents an ICH Q3C risk assessment across all product-contact materials, alongside nitrosamines (per EMA guidance) and elemental impurities (ICH Q3D).
How do I request a DMF Letter of Authorization from an excipient supplier?
Request the Letter of Authorization (LoA) directly from the DMF holder. The LoA lets you cross-reference the DMF in your IND or BLA. For PAN-Biotech's WFI Beyond (Type IV DMF MF044505), request it from PAN-Celltech at info@pan-celltech.com, together with the specification, a representative CoA and the BSE/TSE & ICH Q3 declaration.
Scale-up, formats and supply (16)
Do I need to re-qualify my water when scaling from development to commercial manufacturing?
That depends on your change-control procedure: any change of water grade, supplier or format is assessed by your quality system. Scaling is simpler when one supplier's matched grades and formats cover every scale, so the water's specification and documentation stay constant. PAN-Biotech positions its P-Series-to-CT-Series continuum, and WFI Beyond formats from 500 mL bottles to 1000 L bags, as allowing scale-up without re-qualifying the water; your change control still decides.
What is the difference between research-grade sterile water and GMP Water for Injection?
Research-grade sterile water is for research use only, whereas GMP Water for Injection is made for regulated manufacturing. PAN-Biotech's range shows the difference: Sterile Water for Cell Culture (P-Series; articles P04-991500, P04-991000 and P04-99200B; 500 mL and 1000 mL bottles and a 20 L bag) is for research use only, while WFI Beyond (CT-Series; articles CT-981500 to CT-981000B; 500 mL and 1000 mL bottles and 1–1000 L bags) is a GMP, beyond-compendial Water for Injection with a Certificate of Analysis per lot and a filed FDA Type IV DMF (MF044505). PAN-Biotech positions both as one matched continuum, so development work can move to GMP grade; your change control still applies.
Compendial WFI vs. beyond-compendial WFI: which should I choose?
Compendial WFI meets the Ph. Eur./USP monograph; beyond-compendial WFI is additionally controlled to tighter limits or extra attributes. Choose beyond-compendial water where a sensitive molecule depends on those attributes. PAN-Biotech offers both as GMP CT-Series grades: WFI Quality Water (GMP Water for Injection to EP/USP; articles CT-991500 to CT-99500B) and WFI Beyond (GMP, beyond-compendial; articles CT-981500 to CT-981000B), which is specified at endotoxin < 0.005 EU/mL, nuclease-free, tested for all 24 ICH Q3D elements by ICP-MS and backed by FDA Type IV DMF MF044505. Both grades are released with a Certificate of Analysis per lot.
Can research-use-only water be used in GMP manufacturing?
No – water labelled for research use only is not a GMP grade and is intended for research, not regulated manufacturing. PAN-Biotech's Sterile Water for Cell Culture (P-Series: P04-991500, P04-991000, P04-99200B) is research use only; for GMP work the company offers the CT-Series – WFI Quality Water (EP/USP) and WFI Beyond (beyond-compendial, Type IV DMF MF044505). The two series form a matched continuum; your change control applies to the switch.
How do I choose the right container size for GMP Water for Injection?
Match the container to the process step: small bottles or custom fills for preparation and development work, large single-use bags for production-scale buffer and media preparation. Keeping one supplier and specification across all formats means the water does not change as you scale. PAN-Biotech's WFI Beyond is offered from custom 1 mL tubes and 500 mL or 1000 mL bottles up to single-use bags of 1 to 1000 L.
How can I secure supply continuity for GMP Water for Injection?
Secure continuity by using a qualified supplier with held stock, enough capacity and single-use packaging, so a demand spike or a disrupted incumbent supplier does not force a new qualification. PAN-Celltech, which manufactures PAN-Biotech's WFI Beyond, states GMP capacity of up to ~1.0 million L/year and combined output of up to ~1.8 million L/year. Confirm stock availability for your volumes and formats.
Can a single supplier cover GMP Water for Injection from clinical to commercial volumes?
Yes, if its capacity and formats span both scales. PAN-Celltech, the GMP arm of PAN-Biotech and manufacturer of WFI Beyond, runs a GMP facility with up to ~1.0 million L/year and a combined output of up to ~1.8 million L/year, with WFI Beyond formats from 1 mL custom fills to 1000 L bags. These are stated "up to" capacities, not guaranteed allocations.
How fast can large volumes of GMP Water for Injection be delivered?
Delivery speed depends on the supplier's capacity, stock and scheduling, so ask for documented examples. In one anonymised case study, PAN-Celltech's GMP liquid operation – which also fills PAN-Biotech's WFI Beyond – supplied ~50,000 L for a vaccine programme in under 5 weeks from first production. This illustrates scale but is not a delivery commitment; confirm lead times for your volume and format with PAN-Celltech.
How do I assess a Water for Injection supplier's supply reliability?
Assess reliability through documented evidence: delivery track record, rejection history, stated capacity and the ability to hold stock. PAN-Celltech, manufacturer of PAN-Biotech's WFI Beyond, cites an anonymised case of ~150,000 L (~300,000 bottles) supplied to a contract/OEM customer over ~2 years with zero rejections, and ~50,000 L for a vaccine programme in under 5 weeks. Both describe its GMP liquid operation across products, not WFI Beyond alone.
What is the shelf life of ready-to-use GMP Water for Injection?
Shelf life depends on the supplier's stability data and storage conditions, so check the stability study behind the stated period. PAN-Biotech's WFI Beyond has a shelf life of 2 years at +15 to +25 °C, supported by an ICH-format stability study. Follow the label and specification for storage and handling. Stability data are also part of what its Type IV DMF (MF044505) captures.
Can Water for Injection be produced without distillation?
Yes. PAN-Biotech's WFI Beyond is produced by a membrane-based process, not distillation, and meets the Ph. Eur./USP Water for Injection requirements. Each lot is verified against the Ph. Eur. 0169 attributes and an extended panel: conductivity ≤ 0.2 µS/cm, TOC ≤ 0.05 mg/L, endotoxin < 0.005 EU/mL, nucleases none detected, 24 ICH Q3D elements and sterility.
What happens if I change my Water for Injection supplier after filing?
According to PAN-Biotech, once the water is part of your validated process and regulatory dossier, changing it would trigger re-qualification and a filing change. That is why the water choice is best made early in development. PAN-Biotech's WFI Beyond is designed to be built in from the start: DMF-backed (Type IV, MF044505) and available from 1 mL fills to 1000 L bags, so the same water can stay through commercial supply.
Why buy ready-to-use GMP Water for Injection instead of producing it in-house?
Buying ready-to-use GMP WFI shifts purification, validation, routine testing and documentation from your site to a qualified supplier. PAN-Biotech's WFI Beyond arrives sterile in single-use containers, released with a lot-specific CoA and backed by Type IV DMF MF044505, so it can go straight into buffer preparation or formulation without operating a still, a distribution loop or water-system CIP/SIP. Evaluate total cost of ownership against your own volumes.
How can a CDMO standardise one water grade across client programmes?
A CDMO can standardise by qualifying one DMF-backed water specification and using it for every client programme, instead of qualifying a different water per client. With PAN-Biotech's WFI Beyond, clients can reference Type IV DMF MF044505 in their own IND/BLA through a Letter of Authorization, while the CDMO maintains one specification, one documentation and packaging standard and one audit story. Each client's regulatory and change-control requirements still apply.
Can one water specification support a pipeline that moves between modalities?
Yes – water quality matters for every modality; what changes is which attribute matters most. PAN-Biotech's WFI Beyond uses one specification that covers the priority attributes of five modalities: trace metals and endotoxin (mAbs); nuclease-free status (mRNA & LNP); endotoxin, nucleases and sterility (cell & gene therapy); endotoxin and sterility at scale (vaccines); and endotoxin and TOC (recombinant proteins). Your change control still applies to any modality pivot.
What water attributes matter most for vaccine manufacturing at scale?
For vaccines, the water attributes that matter most are endotoxin control and sterility at scale, because pyrogen safety and batch-to-batch consistency must hold across large production volumes. PAN-Biotech's WFI Beyond is specified at endotoxin < 0.005 EU/mL, is sterile, and is aseptically filled into single-use bags of up to 1000 L. In an anonymised case study, PAN-Celltech's GMP liquid operation supplied ~50,000 L for a vaccine programme in under 5 weeks.
Water for Injection beyond the monograph (9)
What are the Ph. Eur. 0169 limits for Water for Injection?
Ph. Eur. 0169 sets three key quantitative limits for Water for Injection: conductivity ≤ 1.1 µS/cm at 20 °C (method 2.2.38), total organic carbon ≤ 0.5 mg/L (2.2.44) and endotoxin ≤ 0.25 EU/mL (2.6.14). The monograph sets no limits for elemental impurities or nuclease activity. PAN-Biotech's WFI Beyond is specified at ≤ 0.2 µS/cm, ≤ 0.05 mg/L and < 0.005 EU/mL respectively.
Which quality attributes does the WFI monograph not cover?
The Ph. Eur. 0169 WFI monograph does not cover elemental impurities or nuclease (RNase/DNase) activity, and it does not name the impurity classes modern filings address: ICH Q3D elemental impurities, ICH Q3C residual solvents, nitrosamines (EMA guidance) and TSE/BSE status. Iron sits outside both the monograph and ICH Q3D. PAN-Biotech's WFI Beyond adds nuclease testing and ICP-MS for all 24 ICH Q3D elements per lot, measures iron, and covers the rest in a signed declaration.
When was the European Water for Injection standard first defined?
The European Water for Injection standard traces back to the first European Pharmacopoeia, published in 1969. Its limits were framed for the medicine of that era – injectable water in general – not for the specific vulnerabilities of today's biologics, such as nuclease sensitivity or metal-catalysed oxidation. This is why PAN-Biotech treats the monograph as a floor: its WFI Beyond adds attributes such as nuclease activity and all 24 ICH Q3D elements.
What does total organic carbon (TOC) indicate in Water for Injection?
Total organic carbon (TOC) is a general purity marker for organic contamination in water. The Ph. Eur. 0169 limit for WFI is ≤ 0.5 mg/L (method 2.2.44). PAN-Biotech's WFI Beyond is specified at ≤ 0.05 mg/L – 10 times lower – and its reference lot 2560826 measured 0.011 mg/L. Low organic carbon is one of the attributes that matters most for recombinant protein processes, where purity protects the final product and keeps the process clean.
What water quality do recombinant protein processes need?
Recombinant protein processes depend most on low endotoxin and low organic carbon in the water, because purity and pyrogen control protect the final product and keep the process clean. Both are compendial attributes, but the monograph limits are minimums. PAN-Biotech's WFI Beyond is specified at endotoxin < 0.005 EU/mL (Ph. Eur. limit ≤ 0.25 EU/mL) and TOC ≤ 0.05 mg/L (Ph. Eur. limit ≤ 0.5 mg/L), with 0.011 mg/L TOC measured on reference lot 2560826.
How should I compare Water for Injection suppliers beyond the monograph?
Compare WFI suppliers on actual lot data and documentation, not on "meets WFI". Check: measured endotoxin, TOC and conductivity versus Ph. Eur. limits; RNase and DNase results; ICP-MS values for all 24 ICH Q3D elements, plus iron; a filed DMF and Letter of Authorization; BSE/TSE, ICH Q3C and nitrosamine documentation; audit access and format range. PAN-Biotech's WFI Beyond provides each of these; request its specification and a representative CoA.
Where can I buy beyond-compendial GMP Water for Injection?
PAN-Biotech supplies WFI Beyond, a beyond-compendial GMP Water for Injection manufactured by its GMP arm PAN-Celltech under EU GMP Annex 1. It meets the Ph. Eur./USP WFI requirements and adds nuclease-free status, endotoxin < 0.005 EU/mL, lot-by-lot ICP-MS for 24 ICH Q3D elements and Type IV DMF MF044505. It is an excipient for further manufacturing, not for direct human use. Contact: info@pan-celltech.com.
How much tighter than Ph. Eur. 0169 can a Water for Injection specification be?
A Water for Injection specification can sit well below the Ph. Eur. 0169 limits and add attributes the monograph lacks. PAN-Biotech's WFI Beyond is specified more than 5 times below the Ph. Eur. limit for conductivity, 10 times below for TOC and more than 50 times below for endotoxin. Conductivity at 20 °C (Ph. Eur. 2.2.38): Ph. Eur. limit ≤ 1.1 µS/cm; WFI Beyond specification ≤ 0.2 µS/cm; lot 2560826 result 0.128 µS/cm. Total organic carbon (Ph. Eur. 2.2.44): Ph. Eur. limit ≤ 0.5 mg/L; WFI Beyond specification ≤ 0.05 mg/L; lot result 0.011 mg/L. Endotoxin (Ph. Eur. 2.6.14, Method C): Ph. Eur. limit ≤ 0.25 EU/mL; WFI Beyond specification < 0.005 EU/mL; lot result < 0.005 EU/mL. RNase/DNase activity (method AA 4.1.10): not in the monograph; WFI Beyond specification none detected; lot result not detected. Elemental impurities (Ph. Eur. 2.4.20, ICP-MS): not in the monograph; WFI Beyond quantifies all 24 ICH Q3D elements; lot result 22 of 24 below LOQ. Sterility (Ph. Eur. 2.6.1): WFI Beyond is sterile; lot result no growth. These are actual results from Art. CT-981000, Lot 2560826, produced 18 Aug 2026 – not typical or target figures.
What should a Certificate of Analysis for Water for Injection include?
For advanced biologics, a WFI Certificate of Analysis should report actual measured values – not only "complies" – for the compendial attributes and any extra attributes your molecule depends on. PAN-Biotech's WFI Beyond CoA shows, per lot, the Ph. Eur. 0169 limit, specification and result for appearance, conductivity, TOC, endotoxin (beginning and end of fill), RNase/DNase, sterility and all 24 ICH Q3D elements with per-element LOQs, plus an oxidation-metals addendum for copper and iron.